Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy

Journal of Clinical Oncology

Volumn 24, Issue 11, 2006, Pages 1712-1719

  Levine, Alexandra M ^a   Tulpule, Anil ^a   Quinn, David I ^a   Gorospe III, Gerardo ^a   Smith, D Lynne ^a   Hornor, Laurie ^a   Boswell, William D ^a   Espina, Byron M ^a   Groshen, Susan G ^a   Masood, Rizwan ^a   Gill, Parkash S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VEGLIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A; VASCULOTROPIN C;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER FATIGUE; CANCER REGRESSION; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T CELL LYMPHOMA; THYROID CANCER; BLOOD; DRUG ANTAGONISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 33645838598     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.4801     Document Type: Article

References (37)

1. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
2. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
3. Senger DR, Van de Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
4. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
5. Carmeliet P, Ferreira V, Breier B, et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439, 1996
6. Fong GH, Rossant J, Gertsenstin M, et al: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
7. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood island formation and vasculogenesis in Flk-1 deficient mice. Nature 376:62-66, 1995
8. Chan AS, Leung SY, Wong MP, et al: Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligtodendroglioma, and ependymoma. Am J Surg Pathol 22:816-826, 1998
9. Leung SY, Chan AS, Wong MP, et al: Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. Am J Surg Pathol 21:941-950, 1997
10. Dankbar B, Padro T, Leo R, et al: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630-2636, 2000
11. Takahashi T, Shibuya M: The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PCL gamma pathway and partially induces mitotic signals in HIV3T3 fibroblasts. Oncogene 14:2079-2089, 1997
12. Masood R, Cai J, Zheng T, et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi's sarcoma. Proc Natl Acad Sci U S A 94:979-984, 1997
13. Masood R, Cai J, Zheng T, et al: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor positive human tumors. Blood 98:1904-1913, 2001
14. Masood R, Kundra A, Zhu S, et al: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104:603-610, 2003
15. Hotz HG, Hines OJ, Masood R, et al: VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137:192-199, 2005
16. VEGF-Antisense Oligonucleotide (VEGF-AS) (investigator's brochure). Los Angeles, CA: VasGene Therapeutics Inc, 2004
17. Simon RM: Design of clinical trials, in DeVita JM Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice (ed 5). Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 514
18. Raynaud FI, Orr RM, Goddard PM, et al: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-428, 1997
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
20. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
21. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria - AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7:1201-1207, 1989
22. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
23. Zar JH: Paired sample hypothesis, in Biostatistical Analysis. Englewood Cliffs, NJ, Prentice-Hall Inc, 1974, pp 121-129
24. Zar JH: Simple linear correlation, in Biostatistical Analysis. Englewood Cliffs, NJ, Prentice-Hall Inc, 1974, pp 236-251
25. Gill PS, Lunardi-Iskandar Y, Louie S, et al: The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 335:261-269, 1996
26. Gill PS, McLaughlin T, Espina BM, et al: Phase I study of a preparation of human chorionic gonadotropin given subcutaneously to patients with AIDS related Kaposi's sarcoma. J Natl Cancer Inst 89:1797-1892, 1997
27. Noy A, Scadden DT, Lee J, et al: Angiogenesis inhibitor IM 862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM 862 Study Team. J Clin Oncol 23:990-998, 2005
28. Gleadle JM, Ratcliffe PJ: Hypoxia and the regulation of gene expression. Mol Med Today 4:122-129, 1998
29. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858, 1989
30. Neufeld G, Tessler S, Gitay-Goren H, et al: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5:89-97, 1994
31. Millauer B, Wizigmann-Voos S, Schnurch H, et al: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846, 1993
32. Kukk E, Lymboussaki A, Taira S, et al: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a rote in lymphatic vascular development. Development 122:3829-3837, 1996
33. Achen MG, Jeltsch M, Kukk E, et al: Vascular endothelial growth factor D (VEGF-D) is a ligand for tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt 4). Proc Natl Acad Sci U S A 95:548-553, 1998
34. Zanagari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
35. Marx GM, Steer CB, Harper P, et al: Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! J Clin Oncol 20:1446-1448, 2002
36. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002
37. Lee AYY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 107:117-121, 2003